Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Excessive Sweating (Hyperhidrosis) article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Hyperhidrosis (excessive sweating) may be either focal or generalised, and either primary (no underlying cause) or secondary (underlying cause identified). Common triggers include emotion and spicy foods.
- Primary focal hyperhidrosis may affect the axillae, palms, soles or scalp, and has no underlying cause. It usually starts in childhood or adolescence, but can occur at any age. Palmar and plantar hyperhidrosis may be present at birth.
- Secondary focal hyperhidrosis involves specific areas of the body, but is caused by an underlying condition.
- Generalised hyperhidrosis affects the entire body and is usually caused by medical conditions or drugs.
The prevalence of hyperhidrosis is estimated as being about 1% of the population but the true prevalence is unknown, mainly because many affected people are not seen for treatment. Hyperhidrosis occurs both in children and adults, with the average age of onset of primary hyperhidrosis being 14-25 years.
- Drugs - eg, anticholinesterases (pyridostigmine, neostigmine), antidepressants, pilocarpine eye drops, bethanechol, propranolol.
- Substance abuse or withdrawal (including alcohol).
- Heart failure, coronary heart disease, shock.
- Respiratory failure.
- Infections, including tuberculosis, brucellosis, HIV, abscess, and malaria.
- Malignancy, especially lymphoma.
- Thyrotoxicosis, hypoglycaemia, phaeochromocytoma, acromegaly, carcinoid tumour, hyperpituitarism, obesity, gout, menopause.
- Parkinson's disease, diencephalic epilepsy, hypothalamic lesions.
- Familial dysautonomia (Riley-Day syndrome).
Secondary focal hyperhidrosis
- Cerebrovascular disease, peripheral neuropathies, diabetic autonomic neuropathy, spinal cord lesions, and spinal tumours
- Intrathoracic neoplasms - eg, mesothelioma.
- Gustatory sweating (sweating induced by food or drink), which may be due to diabetic neuropathy, preauricular herpes zoster, invasion of the cervical sympathetic trunk (by tumour or injury) or surgery to the parotid gland (eg, Frey's auriculotemporal syndrome).
- Compensatory hyperhidrosis: may occur with myelopathy, cerebrovascular disease, nerve trauma or after surgery. The mechanism of compensatory hyperhidrosis is not clear, but it seems to be associated with compensation for thermoregulatory function.
- Other causes include cervical rib, Raynaud's phenomenon, arteriovenous fistula, cold injury, rheumatoid arthritis, and nail-patella syndrome.
- An underlying cause should be suspected if:
- There is generalised sweating.
- There is sweating during sleep (suggests tuberculosis, another infection, or Hodgkin's disease).
- There are symptoms and signs of systemic disease - eg, fever, weight loss, anorexia, or palpitations.
- The person is taking prescribed drugs that are known to cause sweating.
- There is unilateral or asymmetrical sweating (suggests a neurological lesion or tumour, an intrathoracic malignancy, or a cervical rib).
- There are symptoms and signs of any other causes of secondary focal hyperhidrosis or generalised hyperhidrosis.
- Assess whether anxiety may be an exacerbating factor.
- Diagnose primary focal hyperhidrosis when focal, visible, excessive sweating:
- Occurs in at least one of the following sites: axillae, palms, soles, or craniofacial region; and
- Has lasted at least six months; and
- Has no apparent cause; and
- Has at least two of the following characteristics:
- Bilateral and relatively symmetrical.
- Impairs daily activities.
- Frequency of at least one episode per week.
- Onset before 25 years of age.
- Positive family history.
- Cessation of local sweating during sleep.
- If symptoms have lasted less than six months or onset is at 25 years of age or older, primary focal hyperhidrosis remains a likely diagnosis if other criteria are met, but extra care should be taken to exclude an underlying cause.
If the presentation is characteristic of primary focal hyperhidrosis and there is no evidence of an underlying cause, no laboratory tests are required. Any initial investigations will often depend on individual context of patient and the history and examination but often include:
- FBC; blood film for malarial parasites may be indicated.
- ESR and/or CRP.
- Renal function tests and electrolytes.
- Fasting blood glucose.
- CXR (may be useful to identify an intrathoracic neoplasm or a cervical rib).
- HIV testing.
Generalised hyperhidrosis is usually due to an underlying disorder. Management is therefore directed at finding and treating any underlying cause (usually includes specialist referral).
Primary focal hyperhidrosis
- General advice:
- Avoid clothes that show sweat marks readily (white or black are suitable colours). Wear loose-fitting clothing. Avoid man-made fibres - eg, nylon.
- Soap substitutes reduce skin irritation.
- Avoid any obvious trigger factors.
- Frequently change clothing, including shoes to allow them to dry properly, and avoid heavy occlusive footwear such as boots or sports shoes.
- Primary axillary hyperhidrosis: use an antiperspirant rather than a deodorant; use armpit or sweat shields to absorb excess sweat and protect clothing.
- Primary plantar hyperhidrosis: changing socks at least twice daily; use absorbent soles, and use absorbent foot powder twice daily; avoid occlusive footwear such as boots or sports shoes; wear leather shoes; alternate pairs of shoes on a daily basis to allow them to dry fully.
- 20% aluminium chloride hexahydrate in alcohol solution should be applied to dry skin of the axillae, feet, hands, or face (avoiding the eyes) at night just before sleep, and washed off in the morning. The solution should be applied every 1-2 days until the condition improves and then as required. If successful, treatment can be continued indefinitely.
- Propantheline bromide may be used for hyperhidrosis but its use is limited by systemic antimuscarinic effects.
- Consider treating any underlying anxiety with cognitive behavioural therapy (drug treatment may worsen the hyperhidrosis).
- Refer to a dermatologist if the above measures are inadequate or unacceptable.
- Further treatments in secondary care:
- Modified topical therapy: options include emollients, topical corticosteroids, different strengths of aluminium salts (up to 50%), and topical glutaraldehyde or formaldehyde.
- The sites of hyperhidrosis are immersed in warm water (or a wet contact pad may be applied) through which a weak electric current is passed.
- Glycopyrronium bromide as a 0.05% solution is used in iontophoresis for more severe cases of hyperhidrosis affecting the plantar and palmar areas.
- Some people seem to gain considerable symptom relief. Most report an improvement after 6-10 sessions. Maintenance treatment is usually required at 1- to 4-week intervals.
- Botulinum type A toxin:
- Botulinum A toxin-haemagglutinin complex is licensed for use intradermally for severe hyperhidrosis of the axillae unresponsive to topical antiperspirant or other antihidrotic treatment.
- It is given by repeated intradermal injections into the affected area.
- It has been shown to be safe and effective.
- Usually only considered if other treatment options have failed or have not been tolerated.
- Sympathectomy (division of the sympathetic chain over the neck of the ribs under general anaesthesia) is the most commonly performed procedure:
- The National Institute for Health and Care Excellence (NICE) recommends that current evidence on the efficacy and safety of endoscopic thoracic sympathectomy supports its role in the management of primary hyperhidrosis of the upper limb.
- Lumbar sympathectomy is not used for plantar hyperhidrosis because of the risk of sexual dysfunction.
- Other complications include gustatory sweating, rhinitis, pneumothorax (usually resolves spontaneously), Horner's syndrome, brachial plexus injuries, postoperative neuralgia, and recurrent laryngeal nerve palsy.
- Suction curettage involves using an arthroscopic shaver or similar device to debride the subcutaneous tissue and clear the glands through a small incision:
- It has been used in the management of axillary hyperhidrosis and seems to be well tolerated under local anaesthesia.
- However in a randomised trial, botulin injections were found to be more effective than suction curettage surgery and patients expressed a strong preference for the injections.
- Laser treatment can be used in a similar way to suction curettage and has the potential to offer a permanent solution but there are few clinical data to support the procedure, especially long-term follow-up.
- MiraDry® is a non-invasive procedure that may be effective. It involves using an electromagnetic energy delivered to the skin using a specially designed handpiece.
- Severe hyperhidrosis can cause extreme embarrassment that may lead to social and professional isolation.
- Secondary infections.
Primary focal hyperhidrosis usually runs a chronic course. However the severity of primary hyperhidrosis symptoms often declines with increasing age.
Further reading and references
Hyperhidrosis; NICE CKS, May 2018 (UK access only)
Benson RA, Palin R, Holt PJ, et al; Diagnosis and management of hyperhidrosis. BMJ. 2013 Nov 25347:f6800. doi: 10.1136/bmj.f6800.
Gelbard CM, Epstein H, Hebert A; Primary pediatric hyperhidrosis: a review of current treatment options. Pediatr Dermatol. 2008 Nov-Dec25(6):591-8. doi: 10.1111/j.1525-1470.2008.00782.x.
Haam SJ, Park SY, Paik HC, et al; Sympathetic nerve reconstruction for compensatory hyperhidrosis after sympathetic surgery for primary hyperhidrosis. J Korean Med Sci. 2010 Apr25(4):597-601. doi: 10.3346/jkms.2010.25.4.597. Epub 2010 Mar 19.
British National Formulary (BNF); NICE Evidence Services (UK access only)
Nawrocki S, Cha J; Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol. 2020 Apr82(4):969-979. doi: 10.1016/j.jaad.2019.11.042. Epub 2019 Dec 4.
Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb; NICE Interventional Procedure Guidance, May 2014
Ibrahim O, Kakar R, Bolotin D, et al; The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol. 2013 Jul69(1):88-95. doi: 10.1016/j.jaad.2013.02.013. Epub 2013 Apr 13.
miraDry®; Hyperhidrosis UK